ArticleClinical and molecular hepatology2024
Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide".
Pin-Nan Cheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.